{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:34:48Z","timestamp":1788305688702,"version":"build-2803163510"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"S2","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ital J Pediatr"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1186\/s13052-018-0565-y","type":"journal-article","created":{"date-parts":[[2018,11,14]],"date-time":"2018-11-14T13:08:24Z","timestamp":1542200904000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Gene therapy for mucopolysaccharidoses: in vivo and ex vivo approaches"],"prefix":"10.1186","volume":"44","author":[{"given":"Alessandro","family":"Fraldi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Serafini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolina Cristina","family":"Sorrentino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Gentner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Aiuti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Ester","family":"Bernardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,16]]},"reference":[{"key":"565_CR1","volume-title":"The metabolic and molecular bases of inherited disease","author":"EF Neufeld","year":"2001","unstructured":"Neufeld EF, Muenzer J. The metabolic and molecular bases of inherited disease. New York: McGraw-Hill; 2001."},{"key":"565_CR2","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1017\/S1462399408000550","volume":"10","author":"LA Clarke","year":"2008","unstructured":"Clarke LA. The mucopolysaccharidoses: a success of molecular medicine. Expert Rev Mol Med. 2008;10:e1.","journal-title":"Expert Rev Mol Med"},{"key":"565_CR3","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1126\/science.169.3941.141","volume":"169","author":"EF Neufeld","year":"1970","unstructured":"Neufeld EF, Fratantoni JC. Inborn errors of mucopolysaccharide metabolism. Science. 1970;169:141\u20136.","journal-title":"Science"},{"key":"565_CR4","doi-asserted-by":"publisher","first-page":"v49","DOI":"10.1093\/rheumatology\/ker396","volume":"50","author":"V Valayannopoulos","year":"2011","unstructured":"Valayannopoulos V, Wijburg FA. Therapy for the mucopolysaccharidoses. Rheumatology (Oxford). 2011;50:v49\u201359.","journal-title":"Rheumatology (Oxford)"},{"key":"565_CR5","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/jcpt.12136","volume":"39","author":"H Noh","year":"2014","unstructured":"Noh H, Lee JI. Current and potential therapeutic strategies for mucopolysaccharidoses. J Clin Pharm Ther. 2014;39:215\u201324.","journal-title":"J Clin Pharm Ther"},{"key":"565_CR6","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1146\/annurev-genom-090711-163739","volume":"13","author":"RJ Desnick","year":"2012","unstructured":"Desnick RJ, Schuchman EH. Enzyme replacement therapy for lysosomal diseases: lessons from 20 years of experience and remaining challenges. Annu Rev Genomics Hum Genet. 2012;13:307\u201335.","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"565_CR7","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1007\/s40265-014-0210-z","volume":"74","author":"M Sanford","year":"2014","unstructured":"Sanford M, Lo JH. Elosulfase alfa: first global approval. Drugs. 2014;74:713\u20138.","journal-title":"Drugs"},{"key":"565_CR8","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.ymgme.2014.10.017","volume":"114","author":"JE Fox","year":"2015","unstructured":"Fox JE, Volpe L, Bullaro J, Kakkis ED, Sly WS. First human treatment with investigational rhGUS enzyme replacement therapy in an advanced stage MPS VII patient. Mol Genet Metab. 2015;114:203\u20138.","journal-title":"Mol Genet Metab"},{"key":"565_CR9","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ymgme.2013.11.015","volume":"111","author":"J Muenzer","year":"2014","unstructured":"Muenzer J. Early initiation of enzyme replacement therapy for the mucopolysaccharidoses. Mol Genet Metab. 2014;111:63\u201372.","journal-title":"Mol Genet Metab"},{"key":"565_CR10","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0140-6736(81)91046-1","volume":"2","author":"JR Hobbs","year":"1981","unstructured":"Hobbs JR, Hugh-Jones K, Barrett AJ, Byrom N, Chambers D, Henry K, et al. Reversal of clinical features of Hurler's disease and biochemical improvement after treatment by bone-marrow transplantation. Lancet. 1981;2:709\u201312.","journal-title":"Lancet"},{"key":"565_CR11","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/j.bbmt.2015.02.011","volume":"21","author":"M Aldenhoven","year":"2015","unstructured":"Aldenhoven M, Jones SA, Bonney D, Borrill RE, Coussons M, Mercer J, et al. Hematopoietic cell transplantation for mucopolysaccharidosis patients is safe and effective: results after implementation of international guidelines. Biol Blood Marrow Transplant. 2015;21:1106\u20139.","journal-title":"Biol Blood Marrow Transplant."},{"key":"565_CR12","doi-asserted-by":"publisher","first-page":"2164","DOI":"10.1182\/blood-2014-11-608075","volume":"125","author":"M Aldenhoven","year":"2015","unstructured":"Aldenhoven M, Wynn RF, Orchard PJ, O'Meara A, Veys P, Fischer A, et al. Long-term outcome of hurler syndrome patients after hematopoietic cell transplantation: an international multicenter study. Blood. 2015;125:2164\u201372.","journal-title":"Blood"},{"key":"565_CR13","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1056\/NEJMoa032613","volume":"350","author":"SL Staba","year":"2004","unstructured":"Staba SL, Escolar ML, Poe M, Kim Y, Martin PL, Szabolcs P, et al. Cord-blood transplants from unrelated donors in patients with Hurler's syndrome. N Engl J Med. 2004;350:1960\u20139.","journal-title":"N Engl J Med"},{"key":"565_CR14","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.bbmt.2008.01.009","volume":"14","author":"M Aldenhoven","year":"2008","unstructured":"Aldenhoven M, Boelens JJ, de Koning TJ. The clinical outcome of hurler syndrome after stem cell transplantation. Biol Blood Marrow Transplant. 2008;14:485\u201398.","journal-title":"Biol Blood Marrow Transplant"},{"key":"565_CR15","first-page":"1719","volume":"152","author":"M Aldenhoven","year":"2008","unstructured":"Aldenhoven M, de Koning TJ, Wulffraat NM, Boelens JJ. Umbilical cord blood from an unrelated donor as source for stem cell transplantations in inborn errors of metabolism. Ned Tijdschr Geneeskd. 2008;152:1719\u201324.","journal-title":"Ned Tijdschr Geneeskd"},{"key":"565_CR16","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s10545-015-9900-2","volume":"39","author":"S Tomatsu","year":"2016","unstructured":"Tomatsu S, Azario I, Sawamoto K, Pievani AS, Biondi A, Serafini M, et al. Neonatal cellular and gene therapies for mucopolysaccharidoses: the earlier the better? J Inherit Metab Dis. 2016;39:189\u2013202.","journal-title":"J Inherit Metab Dis"},{"key":"565_CR17","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1038\/nbt.3584","volume":"34","author":"R Palchaudhuri","year":"2016","unstructured":"Palchaudhuri R, Saez B, Hoggatt J, Schajnovitz A, Sykes DB, Tate TA, et al. Non-genotoxic conditioning for hematopoietic stem cell transplantation using a hematopoietic-cell-specific internalizing immunotoxin. Nat Biotechnol. 2016;34:738\u201345.","journal-title":"Nat Biotechnol"},{"key":"565_CR18","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.ymgme.2016.05.015","volume":"118","author":"S Elliott","year":"2016","unstructured":"Elliott S, Buroker CJJ, Potier AM, Trometer JD, Elbin C, et al. Pilot study of newborn screening for six lysosomal storage diseases using tandem mass spectrometry. Mol Genet Metab. 2016;118:304\u20139.","journal-title":"Mol Genet Metab"},{"key":"565_CR19","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1146\/annurev-med-122313-085916","volume":"66","author":"G Parenti","year":"2015","unstructured":"Parenti G, Andria G, Ballabio A. Lysosomal storage diseases: from pathophysiology to therapy. Annu Rev Med. 2015;66:471\u201386.","journal-title":"Annu Rev Med"},{"key":"565_CR20","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.ymthe.2006.01.006","volume":"13","author":"MS Sands","year":"2006","unstructured":"Sands MS, Davidson BL. Gene therapy for lysosomal storage diseases. Mol Ther. 2006;13:839\u201349.","journal-title":"Mol Ther"},{"key":"565_CR21","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/nrg2988","volume":"12","author":"F Mingozzi","year":"2011","unstructured":"Mingozzi F, High KA. Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat Rev Genet. 2011;12:341\u201355.","journal-title":"Nat Rev Genet"},{"key":"565_CR22","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/nrneurol.2013.56","volume":"9","author":"M Simonato","year":"2013","unstructured":"Simonato M, Bennett J, Boulis NM, Castro MG, Fink DJ, Goins WF, et al. Progress in gene therapy for neurological disorders. Nat Rev Neurol. 2013;9:277\u201391.","journal-title":"Nat Rev Neurol"},{"key":"565_CR23","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/S0896-6273(02)01054-1","volume":"36","author":"WM Pardridge","year":"2002","unstructured":"Pardridge WM. Drug and gene delivery to the brain: the vascular route. Neuron. 2002;36:555\u20138.","journal-title":"Neuron"},{"key":"565_CR24","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1385\/MB:30:1:057","volume":"30","author":"WM Pardridge","year":"2005","unstructured":"Pardridge WM. Molecular biology of the blood-brain barrier. Mol Biotechnol. 2005;30:57\u201370.","journal-title":"Mol Biotechnol"},{"key":"565_CR25","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1002\/ana.20150","volume":"56","author":"N Desmaris","year":"2004","unstructured":"Desmaris N, Verot L, Puech JP, Caillaud C, Vanier MT, Heard JM. Prevention of neuropathology in the mouse model of hurler syndrome. Ann Neurol. 2004;56:68\u201376.","journal-title":"Ann Neurol"},{"key":"565_CR26","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1089\/hum.2015.170","volume":"27","author":"LK Winner","year":"2016","unstructured":"Winner LK, Beard H, Hassiotis S, Lau AA, Luck AJ, Hopwood JJ, Hemsley KM. A preclinical study evaluating AAVrh10-based gene therapy for Sanfilippo syndrome. Hum Gene Ther. 2016;27:363\u201375.","journal-title":"Hum Gene Ther"},{"key":"565_CR27","doi-asserted-by":"publisher","first-page":"10229","DOI":"10.1523\/JNEUROSCI.3558-04.2004","volume":"24","author":"A Cressant","year":"2004","unstructured":"Cressant A, Desmaris N, Verot L, Br\u00e9jot T, Froissart R, Vanier MT, et al. Improved behavior and neuropathology in the mouse model of Sanfilippo type IIIB disease after adeno-associated virus-mediated gene transfer in the striatum. J Neurosci. 2004;24:10229\u201339.","journal-title":"J Neurosci"},{"key":"565_CR28","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1038\/sj.mt.6300016","volume":"15","author":"G Liu","year":"2007","unstructured":"Liu G, Chen YH, He X, Martins I, Heth JA, Chiorini JA, Davidson BL. Adeno-associated virus type 5 reduces learning deficits and restores glutamate receptor subunit levels in MPS VII mice CNS. Mol Ther. 2007;15:242\u20137.","journal-title":"Mol Ther"},{"key":"565_CR29","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1089\/hum.2013.238","volume":"25","author":"M Tardieu","year":"2014","unstructured":"Tardieu M, Zerah M, Husson B, de Bournonville S, Deiva K, Adamsbaum C, et al. Intracerebral administration of adeno-associated viral vector serotype rh.10 carrying human SGSH and SUMF1 cDNAs in children with mucopolysaccharidosis type IIIA disease: results of a phase I\/II trial. Hum Gene Ther. 2014;25:506\u201316.","journal-title":"Hum Gene Ther"},{"key":"565_CR30","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.nbd.2011.02.015","volume":"43","author":"DA Wolf","year":"2011","unstructured":"Wolf DA, Lenander AW, Nan Z, Belur LR, Whitley CB, Gupta P, et al. Direct gene transfer to the CNS prevents emergence of neurologic disease in a murine model of mucopolysaccharidosis type I. Neurobiol Dis. 2011;43:123\u201333.","journal-title":"Neurobiol Dis"},{"key":"565_CR31","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1093\/hmg\/ddm223","volume":"16","author":"A Fraldi","year":"2007","unstructured":"Fraldi A, Hemsley K, Crawley A, Lombardi A, Lau A, Sutherland L, et al. Functional correction of CNS lesions in an MPS-IIIA mouse model by intracerebral AAV-mediated delivery of sulfamidase and SUMF1 genes. Hum Molec Genet. 2007;16:2693\u2013702.","journal-title":"Hum Molec Genet"},{"issue":"8","key":"565_CR32","doi-asserted-by":"publisher","first-page":"3254","DOI":"10.1172\/JCI66778","volume":"123","author":"Virginia Haurigot","year":"2013","unstructured":"Haurigot V, Marco S, Ribera A, Garcia M, Ruzo A, Villacampa P, et al. Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy. J Clin Invest.2013;123(8):3254\u201371.","journal-title":"Journal of Clinical Investigation"},{"key":"565_CR33","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1002\/jgm.1480","volume":"12","author":"H Fu","year":"2010","unstructured":"Fu H, DiRosario J, Kang L, Muenzer J, McCarty DM. Restoration of central nervous system alpha-N-acetylglucosaminidase activity and therapeutic benefits in mucopolysaccharidosis IIIB mice by a single intracisternal recombinant adeno-associated viral type 2 vector delivery. J Gene Med. 2010;12:624\u201333.","journal-title":"J Gene Med"},{"key":"565_CR34","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ymthe.2006.02.012","volume":"14","author":"BA Karolewski","year":"2006","unstructured":"Karolewski BA, Wolfe JH. Genetic correction of the fetal brain increases the lifespan of mice with the severe multisystemic disease mucopolysaccharidosis type VII. Mol Ther. 2006;14:14\u201324.","journal-title":"Mol Ther"},{"key":"565_CR35","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/mt.2015.212","volume":"24","author":"NC Sorrentino","year":"2016","unstructured":"Sorrentino NC, Maffia V, Strollo S, Cacace V, Romagnoli N, Manfredi A, et al. A comprehensive map of CNS transduction by eight recombinant adeno-associated virus serotypes upon cerebrospinal fluid administration in pigs. Mol Ther. 2016;24:276\u201386.","journal-title":"Mol Ther"},{"key":"565_CR36","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/mt.2010.257","volume":"19","author":"G Cotugno","year":"2011","unstructured":"Cotugno G, Annunziata P, Tessitore A, et al. Long-term amelioration of feline mucopolysaccharidosis VI after AAV-mediated liver gene transfer. Mol Ther. 2011;19:461\u20139.","journal-title":"Mol Ther"},{"key":"565_CR37","doi-asserted-by":"publisher","first-page":"14894","DOI":"10.1073\/pnas.1413645111","volume":"111","author":"C Hinderer","year":"2014","unstructured":"Hinderer C, Bell P, Gurda BL, Wang Q, Louboutin JP, Zhu Y, et al. Liver-directed gene therapy corrects cardiovascular lesions in feline mucopolysaccharidosis type I. Proc Natl Acad Sci U S A. 2014;111:14894\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"565_CR38","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/S1474-4422(04)00938-X","volume":"3","author":"RO Brady","year":"2004","unstructured":"Brady RO, Schiffmann R. Enzyme-replacement therapy for metabolic storage disorders. Lancet Neurol. 2004;3:752\u20136.","journal-title":"Lancet Neurol"},{"issue":"Suppl 1","key":"565_CR39","first-page":"630","volume":"13","author":"NC Sorrentino","year":"2016","unstructured":"Sorrentino NC, Fraldi A. Brain targeting in MPS-IIIA. Pediatr Endocrinol Rev. 2016;13(Suppl 1):630\u20138.","journal-title":"Pediatr Endocrinol Rev"},{"key":"565_CR40","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1002\/cpt.18","volume":"97","author":"WM Pardridge","year":"2015","unstructured":"Pardridge WM. Targeted delivery of protein and gene medicines through the blood-brain barrier. Clin Pharmacol Ther. 2015;97:347\u201361.","journal-title":"Clin Pharmacol Ther"},{"key":"565_CR41","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1002\/emmm.201202083","volume":"5","author":"NC Sorrentino","year":"2013","unstructured":"Sorrentino NC, D'Orsi L, Sambri I, Nusco E, Monaco C. Spampanato C, et al. A highly secreted sulphamidase engineered to cross the blood-brain barrier corrects brain lesions of mice with mucopolysaccharidoses type IIIA. EMBO Mol Med. 2013;5:675\u201390.","journal-title":"EMBO Mol Med"},{"key":"565_CR42","doi-asserted-by":"publisher","first-page":"2928","DOI":"10.1021\/mp500258p","volume":"11","author":"RJ Boado","year":"2014","unstructured":"Boado RJ, Lu JZ, Hui EK, Pardridge WM. Insulin receptor antibody-sulfamidase fusion protein penetrates the primate blood-brain barrier and reduces glycosoaminoglycans in Sanfilippo type a cells. Mol Pharm. 2014;11:2928\u201334.","journal-title":"Mol Pharm"},{"key":"565_CR43","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/nbt.1515","volume":"27","author":"KD Foust","year":"2009","unstructured":"Foust KD, Nurre E, Montgomery CL, Hernandez A, Chan CM, Kaspar BK. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotech. 2009;27:59\u201365.","journal-title":"Nat Biotech"},{"key":"565_CR44","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1038\/mt.2011.98","volume":"19","author":"H Zhang","year":"2011","unstructured":"Zhang H, Yang B, Mu X, Ahmed SS, Su Q, He R, et al. Several rAAV vectors efficiently cross the blood-brain barrier and transduce neurons and astrocytes in the neonatal mouse central nervous system. Mol Ther. 2011;19:1440\u20138.","journal-title":"Mol Ther"},{"key":"565_CR45","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/mt.2016.25","volume":"24","author":"J Kaminski","year":"2016","unstructured":"Kaminski J, Frederickson R. Special issue on genome editing technologies for gene and cell therapy. Mol Ther. 2016;24:407\u2013654.","journal-title":"Mol Ther"},{"key":"565_CR46","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1089\/hum.2016.103","volume":"27","author":"ME Bernardo","year":"2016","unstructured":"Bernardo ME, Aiuti A. The role of conditioning in hematopoietic stem cell gene therapy. Hum Gene Ther. 2016;27:741\u20138.","journal-title":"Hum Gene Ther"},{"key":"565_CR47","doi-asserted-by":"publisher","first-page":"1233151","DOI":"10.1126\/science.1233151","volume":"341","author":"A Aiuti","year":"2013","unstructured":"Aiuti A, Biasco L, Scaramuzza S, Ferrua F, Cicalese MP. Baricordi C,et al. lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science. 2013;341:1233151.","journal-title":"Science"},{"key":"565_CR48","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1182\/blood-2016-01-688226","volume":"128","author":"MP Cicalese","year":"2016","unstructured":"Cicalese MP, Ferrua F, Castagnaro L, Pajno R, Barzaghi F, Giannelli S, et al. Update on the safety and efficacy of retroviral gene therapy for immunodeficiency due to adenosine deaminase deficiency. Blood. 2016;128:45\u201354.","journal-title":"Blood"},{"key":"565_CR49","doi-asserted-by":"publisher","first-page":"1233158","DOI":"10.1126\/science.1233158","volume":"341","author":"A Biffi","year":"2013","unstructured":"Biffi A, Montini E, Lorioli L, Cesani M, Fumagalli F, Plati T, et al. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science. 2013;341:1233158.","journal-title":"Science"},{"key":"565_CR50","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1002\/jnr.23792","volume":"94","author":"JB Rosenberg","year":"2016","unstructured":"Rosenberg JB, Kaminsky SM, Aubourg P, Crystal RG, Sondhi D. Gene therapy for metachromatic leukodystrophy. J Neurosci Res. 2016;94:1169\u201379.","journal-title":"J Neurosci Res"},{"key":"565_CR51","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1089\/hum.2015.047","volume":"26","author":"MP Cicalese","year":"2015","unstructured":"Cicalese MP, Aiuti A. Clinical applications of gene therapy for primary immunodeficiencies. Hum Gene Ther. 2015;26:210\u20139.","journal-title":"Hum Gene Ther"},{"key":"565_CR52","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1126\/science.aah6192","volume":"353","author":"L Naldini","year":"2016","unstructured":"Naldini L, Trono D, Verma IM. Lentiviral vectors, two decades later. Science. 2016;353:1101\u20132.","journal-title":"Science"},{"key":"565_CR53","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S1096-7192(03)00116-1","volume":"79","author":"Y Zheng","year":"2003","unstructured":"Zheng Y, Rozengurt N, Ryazantsev S, Kohn DB, Satake N, Neufeld EF. Treatment of the mouse model of mucopolysaccharidosis I with retrovirally transduced bone marrow. Mol Genet Metab. 2003;79:233\u201344.","journal-title":"Mol Genet Metab"},{"key":"565_CR54","doi-asserted-by":"publisher","first-page":"19958","DOI":"10.1073\/pnas.0908528106","volume":"106","author":"D Wang","year":"2009","unstructured":"Wang D, Zhang W, Kalfa TA, Grabowski G, Davies S, Malik P, Pan D. Reprogramming erythroid cells for lysosomal enzyme production leads to visceral and CNS cross-correction in mice with hurler syndrome. Proc Natl Acad Sci U S A. 2009;106:19958\u201363.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"565_CR55","doi-asserted-by":"publisher","first-page":"3070","DOI":"10.1172\/JCI28873","volume":"116","author":"A Biffi","year":"2006","unstructured":"Biffi A, Capotondo A, Fasano S, del Carro U, Marchesini S, Azuma H, et al. Gene therapy of metachromatic leukodystrophy reverses neurological damage and deficits in mice. J Clin Invest. 2006;116:3070\u201382.","journal-title":"J Clin Invest"},{"issue":"8","key":"565_CR56","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1172\/JCI200419205","volume":"113","author":"Alessandra Biffi","year":"2004","unstructured":"Biffi A, De Palma M, Quattrini A, Del Carro U, Amadio S, Visigalli I, et al. correction of metachromatic leukodystrophy in the mouse model by transplantation of genetically modified hematopoietic stem cells. J Clin Invest 2004;113:1118\u20131129.","journal-title":"Journal of Clinical Investigation"},{"key":"565_CR57","doi-asserted-by":"publisher","first-page":"58ra84","DOI":"10.1126\/scitranslmed.3001522","volume":"2","author":"B Gentner","year":"2010","unstructured":"Gentner B, Visigalli I, Hiramatsu H, Lechman E, Ungari S, Giustacchini A, et al. Identification of hematopoietic stem cell-specific miRNAs enables gene therapy of globoid leukodystrophy. Science Transl Med. 2010;2:58ra84.","journal-title":"Science Transl Med"},{"key":"565_CR58","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1089\/hum.2014.158","volume":"26","author":"T Wakabayashi","year":"2015","unstructured":"Wakabayashi T, Shimada Y, Akiyama K, Higuchi T, Fukuda T, Kobayashi H, et al. Hematopoietic stem cell gene therapy corrects neuropathic phenotype in murine model of mucopolysaccharidosis type II. Hum Gene Ther. 2015;26:357\u201366.","journal-title":"Hum Gene Ther"},{"key":"565_CR59","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/S0140-6736(16)30374-9","volume":"388","author":"M Sessa","year":"2016","unstructured":"Sessa M, Lorioli L, Fumagalli F, Acquati S, Redaelli D, Baldoli C, et al. Lentiviral haemopoietic stem-cell gene therapy in early-onset metachromatic leukodystrophy: an ad-hoc analysis of a non-randomised, open-label, phase 1\/2 trial. Lancet. 2016;388:476\u201387.","journal-title":"Lancet"},{"key":"565_CR60","doi-asserted-by":"publisher","first-page":"5130","DOI":"10.1182\/blood-2010-04-278234","volume":"116","author":"I Visigalli","year":"2010","unstructured":"Visigalli I, Delai S, Politi LS, Di Domenico C, Cerri F, Mrak E, et al. Gene therapy augments the efficacy of hematopoietic cell transplantation and fully corrects mucopolysaccharidosis type I phenotype in the mouse model. Blood. 2010;116:5130\u20139.","journal-title":"Blood"},{"key":"565_CR61","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1089\/hum.2016.068","volume":"27","author":"I Visigalli","year":"2016","unstructured":"Visigalli I, Delai S, Ferro F, Cecere F, Vezzoli M, Sanvito F, et al. Preclinical testing of the safety and tolerability of LV-mediated above normal alpha-L-iduronidase expression in murine and human hematopoietic cells using toxicology and biodistribution GLP studies. Hum Gene Ther. 2016;27:813\u201329.","journal-title":"Hum Gene Ther"},{"key":"565_CR62","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ymgme.2014.12.001","volume":"114","author":"S Tomatsu","year":"2015","unstructured":"Tomatsu S, Alm\u00e9ciga-D\u00edaz CJ, Monta\u00f1o AM, Yabe H, Tanaka A, Dung VC, et al. Therapies for the bone in mucopolysaccharidoses. Mol Genet Metab. 2015;114:94\u2013109.","journal-title":"Mol Genet Metab"},{"key":"565_CR63","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1089\/scd.2011.0555","volume":"21","author":"F Gatto","year":"2012","unstructured":"Gatto F, Redaelli D, Salvad\u00e8 A, Marzorati S, Sacchetti B, Ferina C, et al. Hurler disease bone marrow stromal cells exhibit altered ability to support osteoclast formation. Stem Cells Dev. 2012;21:1466\u201377.","journal-title":"Stem Cells Dev"},{"key":"565_CR64","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1038\/mt.2013.141","volume":"21","author":"A Sergijenko","year":"2013","unstructured":"Sergijenko A, Langford-Smith A, Liao AY, Pickford CE, McDermott J, Nowinski G, et al. Myeloid\/microglial driven autologous hematopoietic stem cell gene therapy corrects a neuronopathic lysosomal disease. Mol Ther. 2013;21:1938\u201349.","journal-title":"Mol Ther"},{"key":"565_CR65","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.jpeds.2014.09.023","volume":"166","author":"PV Hopkins","year":"2015","unstructured":"Hopkins PV, Campbell C, Klug T, Rogers S, Raburn-Miller J, Kiesling J. Lysosomal storage disorder screening implementation: findings from the first six months of full population pilot testing in Missouri. J Pediatr. 2015;166:172\u20137.","journal-title":"J Pediatr"},{"key":"565_CR66","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1007\/s10875-015-0152-6","volume":"35","author":"J van der Spek","year":"2015","unstructured":"van der Spek J, Groenwold RH, van der Burg M, van Montfrans JM. TREC based newborn screening for severe combined immunodeficiency disease: a systematic review. J Clin Immunol. 2015;35:416\u201330.","journal-title":"J Clin Immunol"},{"key":"565_CR67","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1002\/mas.21463","volume":"35","author":"D Ombrone","year":"2016","unstructured":"Ombrone D, Giocaliere E, Forni G, Malvagia S, La Marca G. Expanded newborn screening by mass spectrometry: new tests, future perspectives. Mass Spectrom Rev. 2016;35:71\u201384.","journal-title":"Mass Spectrom Rev"},{"key":"565_CR68","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.stemcr.2017.02.010","volume":"8","author":"E Zonari","year":"2017","unstructured":"Zonari E, Desantis G, Petrillo C, Boccalatte FE, Lidonnici MR, Kajaste-Rudnitski A, et al. Efficient ex vivo engineering and expansion of highly purified human hematopoietic stem and progenitor cell populations for gene therapy. Stem Cell Reports. 2017;8:977\u201390.","journal-title":"Stem Cell Reports"}],"container-title":["Italian Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13052-018-0565-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13052-018-0565-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13052-018-0565-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,16]],"date-time":"2019-11-16T00:18:54Z","timestamp":1573863534000},"score":1,"resource":{"primary":{"URL":"https:\/\/ijponline.biomedcentral.com\/articles\/10.1186\/s13052-018-0565-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":68,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["565"],"URL":"https:\/\/doi.org\/10.1186\/s13052-018-0565-y","relation":{},"ISSN":["1824-7288"],"issn-type":[{"value":"1824-7288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"16 November 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AA is the Principal Investigator of the TIGET-MLD clinical trial sponsored by GlaxoSmithKline (GSK). The remaining authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"130"}}